Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
Monopar Therapeutics Inc. (Nasdaq: MNPR) has filed a provisional patent for new therapeutic radiopharmaceuticals based on a family of linkers connecting radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101. The patent filing covers:
- Composition of Matter: Claims for a family of linkers and Monopar's uPAR targeting agents linked with these and therapeutic radioisotopes
- Stability and Biodistribution: Proprietary new linkers designed to enhance stability and biodistribution of Monopar's therapeutic radiopharmaceuticals
- Versatility: The new linker family works with various isotopes and targeting molecules, including small molecules/peptides and antibodies
The company believes these linkers could create new proprietary radiopharmaceuticals targeting high-value cancer targets and potentially lead to licensing and development collaborations in the industry.
Monopar Therapeutics Inc. (Nasdaq: MNPR) ha presentato un brevetto provvisorio per nuovi radiofarmaci terapeutici basati su una famiglia di linkers che collegano radioisotopi con agenti di targeting, incluso l'anticorpo in target uPAR di Monopar, MNPR-101. La domanda di brevetto comprende:
- Composizione della Materia: Rivendicazioni per una famiglia di linkers e agenti di targeting uPAR di Monopar collegati a questi e radioisotopi terapeutici
- Stabilità e Biodistribuzione: Linkers nuovi e proprietari progettati per migliorare la stabilità e la biodistribuzione dei radiofarmaci terapeutici di Monopar
- Versatilità: La nuova famiglia di linkers funziona con vari isotopi e molecole di targeting, inclusi piccoli molecole/peptidi e anticorpi
L'azienda crede che questi linkers potrebbero creare nuovi radiofarmaci proprietari che mirano a obiettivi oncologici di alto valore e potrebbero portare a collaborazioni di licenza e sviluppo nel settore.
Monopar Therapeutics Inc. (Nasdaq: MNPR) ha presentado una patente provisional para nuevos radiofármacos terapéuticos basados en una familia de conectores que unen radioisótopos con agentes de localización, incluyendo el anticuerpo de localización uPAR de Monopar, MNPR-101. La solicitud de patente cubre:
- Composición de Materia: Reclamaciones para una familia de conectores y agentes de localización uPAR de Monopar vinculados a estos y radioisótopos terapéuticos
- Estabilidad y Biodistribución: Nuevos conectores propietarios diseñados para mejorar la estabilidad y biodistribución de los radiofármacos terapéuticos de Monopar
- Versatilidad: La nueva familia de conectores funciona con varios isótopos y moléculas de localización, incluyendo pequeñas moléculas/ péptidos y anticuerpos
La empresa cree que estos conectores podrían crear nuevos radiofármacos propietarios que apunten a objetivos de cáncer de alto valor y potencialmente conducir a colaboraciones de licenciamiento y desarrollo en la industria.
모노파 치료제 주식회사 (Nasdaq: MNPR)는 방사성 동위원소와 표적 제제를 연결하는 링커의 한 가족을 기반으로 한 새로운 치료 방사성 의약품에 대한 잠정 특허를 출원하였습니다. 여기에는 모노파의 uPAR 표적 항체 MNPR-101이 포함됩니다. 특허 출원은 다음을 포함합니다:
- 물질의 조성: 이 링커들과 연결된 모노파의 uPAR 표적 제제 및 치료 방사성 동위원소에 대한 링커 가족에 대한 청구
- 안정성 및 생체 분포: 모노파의 치료 방사성 의약품의 안정성과 생체 분포를 향상시키기 위해 설계된 독점 새로운 링커
- 다재다능성: 새로운 링커 가족은 다양한 동위원소 및 표적 분자, 작은 분자/펩타이드 및 항체와 함께 작동합니다
회사는 이러한 링커가 고가치 암 표적을 목표로 하는 새로운 독점 방사성 의약품을 창출할 수 있으며, 잠재적으로 업계의 라이센스 및 개발 협력으로 이어질 수 있다고 믿고 있습니다.
Monopar Therapeutics Inc. (Nasdaq: MNPR) a déposé un brevet provisoire pour de nouveaux radio-pharmaceutiques thérapeutiques basés sur une famille de liaisons reliant des radio-isotopes à des agents de ciblage, y compris l'anticorps ciblant uPAR de Monopar, MNPR-101. La demande de brevet couvre:
- Composition de Matériau: Revendications pour une famille de liaisons et les agents de ciblage uPAR de Monopar liés à ceux-ci et aux radio-isotopes thérapeutiques
- Stabilité et Biodistribution: Nouveaux liaisons propriétaires conçus pour améliorer la stabilité et la biodistribution des radio-pharmaceutiques thérapeutiques de Monopar
- Polyvalence: La nouvelle famille de liaisons fonctionne avec divers isotopes et molécules de ciblage, y compris de petites molécules/peptides et des anticorps
La société pense que ces liaisons pourraient créer de nouveaux radio-pharmaceutiques propriétaires ciblant des cibles de cancer à haute valeur et pourraient potentiellement conduire à des collaborations de licence et de développement dans l'industrie.
Monopar Therapeutics Inc. (Nasdaq: MNPR) hat ein vorläufiges Patent für neue therapeutische Radiopharmazeutika angemeldet, das auf einer Familie von Linkern basiert, die Radioisotope mit Targeting-Agenten verbinden, einschließlich des uPAR-targetierenden Antikörpers MNPR-101 von Monopar. Die Patentanmeldung umfasst:
- Materie Zusammensetzung: Ansprüche für eine Familie von Linkern und Monopars uPAR-Targeting-Agenten, die mit diesen und therapeutischen Radioisotopen verbunden sind
- Stabilität und Biodistribution: Proprietäre neue Linker, die entwickelt wurden, um die Stabilität und Biodistribution von Monopars therapeutischen Radiopharmazeutika zu verbessern
- Vielseitigkeit: Die neue Linker-Familie funktioniert mit verschiedenen Isotopen und Targeting-Molekülen, einschließlich kleiner Moleküle/Petptide und Antikörpern
Das Unternehmen glaubt, dass diese Linker neue proprietäre Radiopharmazeutika schaffen könnten, die auf hochpreisige Krebsziele abzielen und potenziell zu Lizenz- und Entwicklungskooperationen in der Branche führen könnten.
- Filing of a provisional patent for new therapeutic radiopharmaceuticals
- Potential for creating new proprietary radiopharmaceuticals targeting high-value cancer targets
- Possibility of licensing and development collaborations in the industry
- None.
Insights
This patent filing represents a significant step forward in Monopar's radiopharmaceutical development efforts. The new family of linkers could potentially enhance the stability and biodistribution of therapeutic radiopharmaceuticals, which are critical factors in their efficacy and safety profiles. The versatility of these linkers, working with various isotopes and targeting molecules, suggests broad applicability across different cancer types and targeting strategies.
The composition of matter claims, if granted, could provide Monopar with a strong intellectual property position in the rapidly growing radiopharmaceutical market. This could translate into long-term value for the company, either through in-house development of novel radiopharmaceuticals or through licensing agreements with other players in the field.
However, it's important to note that this is a provisional patent filing and the path to a granted patent and eventual commercialization is long and uncertain. The true value of this intellectual property will depend on the strength of the final patent claims and the clinical performance of radiopharmaceuticals developed using these linkers.
Monopar's patent filing is strategically significant in the competitive landscape of radiopharmaceuticals. The company is positioning itself at the intersection of two hot areas in oncology: targeted therapies and radiopharmaceuticals. By developing proprietary linker technology, Monopar is creating potential barriers to entry and differentiation from competitors.
The mention of potential licensing and development collaborations is particularly noteworthy. For a small-cap company like Monopar (
Investors should watch for any announcements regarding preclinical or clinical data using these new linkers, as well as any partnership deals. These would be key indicators of the technology's potential value. However, given the early stage of this development, any impact on revenue is likely several years away and significant R&D investment will be required to bring these concepts to market.
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody MNPR-101.
Highlights of the patent filing include:
- Composition of Matter: Claims cover a family of linkers, as well as Monopar’s uPAR targeting agents linked with these along with therapeutic radioisotopes
- Stability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar’s array of therapeutic radiopharmaceuticals
- Versatility: The newly developed linker family works with a wide range of isotopes and targeting molecules, including small molecules/peptides and antibodies
“This provisional patent could enable us to use these linkers to create new proprietary radiopharmaceuticals going after well-established, high-value cancer targets that we are interested in,” commented Andrew Cittadine, Monopar’s Chief Operating Officer. “We also believe that these linkers may be of great interest to others in the industry, opening the door to potential licensing and development collaborations.”
“These novel linkers and compositions of matter exemplify Monopar’s passion and commitment to being an innovator in the radiopharma space,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that these proprietary new linkers have been created to enhance the stability and biodistribution of Monopar’s array of therapeutic radiopharmaceuticals; that this newly developed linker family works with a wide range of isotopes and targeting molecules, including small molecules/peptides and antibodies; and that this provisional patent could enable Monopar to use these linkers to create new proprietary radiopharmaceuticals going after well-established, high-value cancer targets of interest to Monopar or others in the industry opening the door to potential licensing and development collaborations. The forward-looking statements involve risks and uncertainties including, but not limited to: that the new linker family may not be as stable in humans as anticipated; that patent applications may not result in allowed patents; that if allowed, the patents may be too narrow in scope to provide protection needed to successfully develop the radiopharma program; that we may expend available funds sooner than anticipated or require additional funding due to change in circumstances or unanticipated events; that future preclinical or clinical data will not be as promising as the data to date; not successfully enrolling the MNPR-101-Zr Phase 1 and/or the MNPR-101-Lu clinical trials; that MNPR-101-Zr and/or MNPR-101-Lu may cause unexpected serious adverse effects or fail to image or be effective against the cancer tumors in humans; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
What did Monopar Therapeutics (MNPR) announce on October 15, 2024?
What are the key features of Monopar's (MNPR) new patent filing?
How might Monopar's (MNPR) new linker technology benefit the company?
What is the significance of Monopar's (MNPR) patent filing for the radiopharma industry?
